Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences Announces its Addition to the Russell Microcap® Index
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
- PBGENE-HBV specifically cuts HBV DNA without impacting the human genome - PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed - Preclinical safety data…
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--May 30, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene editing…
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop…
Precision BioSciences to Report First Quarter Results on May 13, 2024
DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2024-- Precision BioSciences,…
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and…
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
- Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 - Completed licensing agreements to monetize divested CAR T assets…